Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: The diagnostic significance of interleukin-18 and interleukin-6

► MAS could develop even during TCZ therapy. ► TCZ masks the clinical symptoms of s-JIA-associated MAS. ► We should be careful for persistent increase of serum IL-18.